RETN and neoplasm: A previous study showed that the resistin levels in CRC patients were significantly higher than a matched control group, and the concentration of resistin gradually increased as the tumor stage progressed [22], which indicated that resistin is a convincing biomarker for the progression of CRC malignancy.